Wave Life Sciences, Inc. (FRA:0VS)
Germany · Delayed Price · Currency is EUR | Market Cap | 556.81M -47.8% |
| Revenue (ttm) | 57.22M -30.4% |
| Net Income | -177.22M |
| EPS | -0.94 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.600 |
| Previous Close | 2.645 |
| Day's Range | 2.600 - 2.710 |
| 52-Week Range | 2.555 - 17.800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 10, 2026 |
About Wave Life Sciences
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscula... [Read more]
Financial Performance
In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Wave Life Sciences Transcript: Chardan's 10th Annual Healthcare Conference
WVE-007 showed fat reduction with lean-mass preservation in phase I, while phase IIa obesity and combination studies advance. Alpha-1 antitrypsin RNA editing showed consistent patient responses, with a two-year registrational design and possible one-year interim analysis for accelerated approval.
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
CAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences initiated with an Outperform at William Blair
William Blair initiated coverage of Wave Life Sciences (WVE) with an Outperform rating. Wave is a clinical-stage RNA medicines company advancing WVE-006 toward registrational development for AATD and ...
Wave Life Sciences initiated with a Buy at UBS
UBS initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $11 price target Wave is a leader in RNA editing therapeutic development with positive human proof of…
Wave Life Sciences Proxy statement: Proxy filing
Wave Life Sciences filed a proxy statement on October 14, 2026, providing details for shareholder voting and corporate governance matters.
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences announces FDA feedback supports pathway for WVE-006
Wave Life Sciences (WVE) announced alignment with the U.S. Food and Drug Administration, FDA, on key aspects of its planned registrational pathway for WVE-006, an investigational GalNAc-RNA editing ol...
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers
Wave Life Sciences initiated with a Buy at Ladenburg
Ladenburg analyst Rick Bienkowski initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $10 price target
Wave Life announces GSK’s selection of siRNA program to transition to GSK
Wave Life Sciences (WVE) announced that as part of the companies’ research collaboration, GSK (GSK) has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. ...
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
Wave Life Sciences resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Wave Life Sciences (WVE) with a Neutral rating and no price target Share upside will be tied to WVE-007 and if the drug can meet the…
Wave Life Sciences initiates Phase 2a combination trial of WVE-007
Wave Life Sciences (WVE) announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combination with tirzepatide in adults living with obesity. The...
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss c...
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
RNA editing has advanced with highly specific, durable correction in clinical programs like AATD and PNPLA3, supported by chemistry innovations and new trial designs. The Inhibin E program is progressing in obesity and cardiometabolic disease, with data and regulatory milestones expected this year.
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
The discussion highlighted rapid progress in RNA medicines, with INHBE showing promising fat loss and safety in obesity, and WVE-006 advancing for AATD with a biomarker-driven regulatory path. Strategic interest remains strong, and new studies will address combination and maintenance therapies.
Wave Life Sciences Transcript: Bank of America SMID Cap Virtual Conference
The conference highlighted advances in RNA-based therapeutics, with WVE-007 and AATD programs poised for significant milestones in the next year. Strategic partnerships and a strong cash position support ongoing clinical progress and expansion into cardiometabolic indications.
Wave Life Sciences announces completion of redomiciliation to Delaware
Wave Life Sciences (WVE) announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation.
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...